AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
Posted on 16 Nov 2026
Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women. Researchers presenting at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo highlighted studies demonstrating how molecular testing and epigenetic profiling could support more precise diagnosis, treatment decisions, and individualized patient care.
The AMP 2026 Annual Meeting & Expo, held November 10–14 at the Seattle Convention Center in Seattle, Washington, brought together molecular pathology professionals to discuss developments in diagnostic testing and precision medicine. Among the research presented were two studies addressing antimicrobial resistance in sexually transmitted infections and molecular risk stratification in endometrial cancer.
Researchers at Unified Women's Healthcare and Alline (formerly Florida Woman Care) analyzed 121,966 vaginal swab specimens to investigate the prevalence of Mycoplasma genitalium, a sexually transmitted pathogen associated with cervicitis and pelvic inflammatory disease. Among 4,605 positive specimens with evaluable results, 41.5% showed resistance to macrolide antibiotics, highlighting the importance of resistance testing in guiding treatment decisions.
The researchers also implemented an automated reflex testing algorithm that achieved a median turnaround time of four days. The findings demonstrate the feasibility of incorporating resistance-guided testing into high-volume women's healthcare settings, supporting treatment approaches recommended by the U.S. Centers for Disease Control and Prevention (CDC).
In a separate oncology study, researchers at the University of California, San Francisco analyzed DNA methylation patterns in 219 tumors to investigate recurrence risk in patients with low-grade, limited-stage, copy number–low endometrioid adenocarcinoma, the most common type of endometrial cancer. The analysis identified methylation patterns strongly associated with recurrence risk, suggesting that epigenetic profiling could help distinguish patients whose tumors share similar conventional clinical and pathological characteristics.
The researchers also identified differences in molecular alterations across methylation-defined tumor groups, including enrichment of CTNNB1 and DICER1 mutations and copy number gains involving chromosome 1q. These findings suggest that DNA methylation profiling could provide additional information about tumor biology and potentially improve recurrence risk stratification beyond conventional pathological assessment.
Together, the studies presented at AMP 2026 highlight the expanding role of molecular diagnostics in women's healthcare, from identifying antibiotic resistance to improving cancer recurrence risk assessment. The findings demonstrate how integrating molecular and epigenetic information into diagnostic workflows could support more personalized treatment decisions and improve clinical management.
Related Links
Association for Molecular Pathology